These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 15113106)

  • 1. Molecular profiling of experimental Parkinson's disease: direct analysis of peptides and proteins on brain tissue sections by MALDI mass spectrometry.
    Pierson J; Norris JL; Aerni HR; Svenningsson P; Caprioli RM; Andrén PE
    J Proteome Res; 2004; 3(2):289-95. PubMed ID: 15113106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MALDI imaging mass spectrometry of neuropeptides in Parkinson's disease.
    Hanrieder J; Ljungdahl A; Andersson M
    J Vis Exp; 2012 Feb; (60):. PubMed ID: 22370902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased levels of ubiquitin in the 6-OHDA-lesioned striatum of rats.
    Pierson J; Svenningsson P; Caprioli RM; Andren PE
    J Proteome Res; 2005; 4(2):223-6. PubMed ID: 15822896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: intrastriatal microinjection studies in the 6-OHDA-lesioned rat.
    Nash JE; Brotchie JM
    Mov Disord; 2002 May; 17(3):455-66. PubMed ID: 12112191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unilateral 6-hydroxydopamine lesion of dopamine neurons and subchronic L-DOPA administration in the adult rat alters the expression of the vesicular GABA transporter in different subsets of striatal neurons and in the substantia nigra, pars reticulata.
    Wang H; Katz J; Dagostino P; Soghomonian JJ
    Neuroscience; 2007 Mar; 145(2):727-37. PubMed ID: 17218060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity.
    Paolone G; Brugnoli A; Arcuri L; Mercatelli D; Morari M
    Mov Disord; 2015 Nov; 30(13):1728-38. PubMed ID: 26207892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of benserazide on L-DOPA-derived extracellular dopamine levels and aromatic L-amino acid decarboxylase activity in the striatum of 6-hydroxydopamine-lesioned rats.
    Shen H; Kannari K; Yamato H; Arai A; Matsunaga M
    Tohoku J Exp Med; 2003 Mar; 199(3):149-59. PubMed ID: 12703659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Supersensitization of neurochemical responses by L-DOPA and dopamine receptor agonists in the striatum of experimental Parkinson's disease model rats.
    Ueda H; Sato K; Okumura F; Inoue A; Nakata Y; Ozaki N; Yue JL; Misu Y
    Biomed Pharmacother; 1995; 49(4):169-77. PubMed ID: 7669936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MK801 influences L-DOPA-induced dopamine release in intact and hemi-parkinson rats.
    Jonkers N; Sarre S; Ebinger G; Michotte Y
    Eur J Pharmacol; 2000 Nov; 407(3):281-91. PubMed ID: 11068024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Striatal activation by optogenetics induces dyskinesias in the 6-hydroxydopamine rat model of Parkinson disease.
    F Hernández L; Castela I; Ruiz-DeDiego I; Obeso JA; Moratalla R
    Mov Disord; 2017 Apr; 32(4):530-537. PubMed ID: 28256089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel dopamine releasing response of an anti-convulsant agent with possible anti-Parkinson's activity.
    Gluck MR; Santana LA; Granson H; Yahr MD
    J Neural Transm (Vienna); 2004 Jun; 111(6):713-24. PubMed ID: 15168218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Denervation and repeated L-DOPA induce complex regulatory changes in neurochemical phenotypes of striatal neurons: implication of a dopamine D1-dependent mechanism.
    St-Hilaire M; Landry E; Lévesque D; Rouillard C
    Neurobiol Dis; 2005 Nov; 20(2):450-60. PubMed ID: 15896973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular imaging of biological samples: localization of peptides and proteins using MALDI-TOF MS.
    Caprioli RM; Farmer TB; Gile J
    Anal Chem; 1997 Dec; 69(23):4751-60. PubMed ID: 9406525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of l-dopa on attentional impairments in a rat model of Parkinson's disease.
    Smith ES; Hardy GA; Schallert T; Lee HJ
    Neuroscience; 2016 Nov; 337():295-305. PubMed ID: 27664460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease.
    Oiwa Y; Yoshimura R; Nakai K; Itakura T
    Brain Res; 2002 Aug; 947(2):271-83. PubMed ID: 12176170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. β-asarone and levodopa coadministration increases striatal levels of dopamine and levodopa and improves behavioral competence in Parkinson's rat by enhancing dopa decarboxylase activity.
    Huang L; Deng M; Zhang S; Lu S; Gui X; Fang Y
    Biomed Pharmacother; 2017 Oct; 94():666-678. PubMed ID: 28787702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesions.
    Datla KP; Blunt SB; Dexter DT
    Mov Disord; 2001 May; 16(3):424-34. PubMed ID: 11391735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. L-DOPA disrupts adenosine A(2A)-cannabinoid CB(1)-dopamine D(2) receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: biochemical and behavioral studies.
    Pinna A; Bonaventura J; Farré D; Sánchez M; Simola N; Mallol J; Lluís C; Costa G; Baqi Y; Müller CE; Cortés A; McCormick P; Canela EI; Martínez-Pinilla E; Lanciego JL; Casadó V; Armentero MT; Franco R
    Exp Neurol; 2014 Mar; 253():180-91. PubMed ID: 24412491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Multimodal Serotonergic Agent Vilazodone Inhibits L-DOPA-Induced Gene Regulation in Striatal Projection Neurons and Associated Dyskinesia in an Animal Model of Parkinson's Disease.
    Altwal F; Moon C; West AR; Steiner H
    Cells; 2020 Oct; 9(10):. PubMed ID: 33050305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The alpha(2) adrenoceptor antagonist idazoxan alleviates L-DOPA-induced dyskinesia by reduction of striatal dopamine levels: an in vivo microdialysis study in 6-hydroxydopamine-lesioned rats.
    Buck K; Voehringer P; Ferger B
    J Neurochem; 2010 Jan; 112(2):444-52. PubMed ID: 19895663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.